Edgewise Therapeutics, Inc.

Historical 13F Holders

Symbol
EWTX
CUSIP
28036F105
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 28036F105 since 12/18/2024, largest first.

Filer % of Class Filed
Orbimed Advisors LLC 13D/A
14.5% 5/12/2025
Event 5/9/2025
Paradigm Biocapital Advisors LP 13G/A
9.5% 8/14/2026
Event 6/30/2026
RA Capital Management, L.P. 13G/A
7.8% 8/14/2026
Event 6/30/2026
Janus Henderson Group Ltd. 13G/A 6.7% 11/16/2026
Event 9/30/2026
BlackRock, Inc. 13G/A 5.5% 7/17/2025
Event 6/30/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
Novo Holdings A/S 13D/A 4.9% 4/27/2026
Event 4/23/2026
Perceptive Advisors LLC 13G/A
4.4% 8/14/2025
Event 6/30/2025
Baker Bros. Advisors LP 13G/A
3.4% 8/14/2026
Event 6/30/2026
FMR LLC 13G/A
0.9% 11/5/2026
Event 9/30/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 254 125 M $5.08B
2026 Q2 228 119 M $4.82B
2026 Q1 217 119 M $3.72B
2025 Q4 203 122 M $3.02B
2025 Q3 177 112 M $1.82B
2025 Q2 180 119 M $1.56B
2025 Q1 201 105 M $2.32B
2024 Q4 208 99.0 M $2.64B
2024 Q3 181 101 M $2.70B
2024 Q2 141 102 M $1.83B
2024 Q1 130 91.6 M $1.67B
2023 Q4 117 79.6 M $871M
2023 Q3 86 68.4 M $392M
2023 Q2 96 69.5 M $539M
2023 Q1 86 66.5 M $443M
2022 Q4 92 66.6 M $595M
2022 Q3 96 64.4 M $634M
2022 Q2 79 51.0 M $406M
2022 Q1 73 54.0 M $524M
2021 Q4 59 50.3 M $769M
2021 Q3 49 48.0 M $796M
2021 Q2 47 47.9 M $1.03B
2021 Q1 32 45.7 M $1.48B